We are engaged in offering Iressa, a targetted therapy. It is classified as a signal transduction inhibitor, epidermal growth factor receptor (EGFR), and tyrosine kinase inhibitor. Iressa is widely used for treating locally advanced or metastatic non-small cell lung cancer, after failure of both platinum-based and taxane-based chemotherapies.

This tablet is used in treatment of patients with locally advanced or metastatic non small cell lung cancer who have previously received chemotherapy.